Sun Pharmaceutical Industries Ltd.'s acquisition of Concert Pharmaceuticals Inc. added a complementary derma product to its existing line of specialty products, according to Jefferies. The brokerage expects a pre-tax net present value of Rs 64 per share from the acquisition of the U.S.-based late-stage clinical biopharmaceutical company on March 6. The brokerage continues to maintain a "buy" rating on the stock and a target price of Rs 1,200 apiece, implying an upside of 26%. The return potential of the stock implies an upside of 20.8%. Source - https://www.bqprime.com/business/sun-pharma-gets-complementary-derma-product-on-buying-concert-pharma-jefferies